Page 30 - Medication Guide News Today

The Phase 3 GRAPHITE Study Met Its Primary Efficacy Endpoint of Significant and Clinically Meaningful Intestinal aGvHD-Free Survival as Compared to Placebo by Day 180 after Allo-HSCT No New... | February 18, 2023

The Phase 3 GRAPHITE Study Met Its Primary Efficacy Endpoint of Significant and Clinically Meaningful Intestinal aGvHD-Free Survival as Compared to Placebo by Day 180 after Allo-HSCT (pNo New Safety Signals Were Seen with Vedolizumab Compared with Placebo in Patients Who Received Allo-HSCTData Were Presented as A La...

The influencer opens up about the beauty treatment that helps her look effortlessly put together.

/PRNewswire/ -- Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today the commercial launch and dosing of...

On January 4, the Food and Drug Administration (FDA) approved modifications to the Risk Evaluation and Mitigation Strategies (REMS) program for the medication abortion drug...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - February 7, 2023 Idorsia Ltd (SIX: IDIA) today announced its financial results for 2022. Commercial highlights QUVIVIQ

/PRNewswire/ -- Guerbet, a global leader in medical imaging with more than 30 years of experience in MRI, announced today the first production batch has been...

The Food and Drug Administration (the “FDA”) has approved a modification to the Mifepristone Risk Evaluation and Mitigation Strategy (“REMS”) Program, increasing the accessibility of...

The FDA approved a modification to the Mifepristone Risk Evaluation and Mitigation Strategy, REMS, Program. The FDA’s approval of commercial dispensing of mifepristone likely will not change the current practice of prescribing and dispensing mifepristone for abortion.

Now newlyweds, Kate Austin and Sarah Sulsenti reflect back on their romantic journey, leading up to the most important milestone of their lives.